Frontlight ResearchEarly access
Taking peoplePhase 3
Randomised, double-blind, multicentre, phase III clinical trial to evaluate the efficacy and safety of dexamethasone compared to placebo in patients with severe influenza (FLUDEX)
Key facts
- Who runs it
- Fundacion De La Comunitat Valenciana Para La Gestion Del Instituto De Investigacion Sanitaria Y Biomedica De Alicante
- Where
- Spain11 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 486 people, planned
- Started
- 20 Nov 2024
- Expected to end
- 1 Oct 2028
- Type of study
- Interventional
- Record updated
- 28 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Aged ≥ 18 years
- Diagnosis of influenza A or B virus infection by antigen or RT-PCR (local laboratory) at the time of entry or at 48 hours prior to randomization in respiratory specimens (nasopharyngeal swab or bronchoalveolar lavage)
- Hospitalized patients with an estimated hospital stay of more than 24 hours
- In previous treatment or concomitant start of treatment with oseltamivir
- For women of childbearing age, use of contraceptive methods until day 30 after completion of treatment
- Signed informed consent
Who cannot take part
- Patients with bronchial hyperresponsiveness that requires systemic corticosteroids for more than 24 hours
- Pre-inclusion treatment with corticosteroids for more than 24 hours at a dose equal to or higher than 1 mg/kg methyl-prednisolone (0.2 mg/kg dexamethasone or 1.25 mg/kg prednisone)
- Pre-existing condition or use of medication that, in the opinion of the local investigator, may pose a risk for the administration of corticosteroids
- Patients co-infected with SARS-CoV-2 or RSV
- Inability to administer oral oseltamivir
- Patients on ECMO (extracorporeal membrane oxygenation)
- Patients with severe comorbidity with life expectancy of less than six months in the opinion of the investigator
This trial is currently available in Spain.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To compare the percentage of patients hospitalized with influenza according to treatment arm (oseltamivir-dexamethasone vs oseltamivir-placebo) with status 3 or higher according to the Hospital Recovery Scale (status 3: hospitalization with supplemental oxygen, or 4: ICU admission without invasive mechanical ventilation, or 5: with invasive mechanical ventilation, or 6: death) on day 7 after the start of treatment.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 28 October 2026